A-1331852
Cat. No.：YN270390
CAS No. ：1430844-80-6
| 产品名称: | A-1331852 |
| CAS No.: | 1430844-80-6 |
| Chemical Name: | 6-[8-[(2-benzothiazolylamino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid |
| Synonyms: | A 1331852,A1331852 |
| 分子量: | 658.81 |
| 分子式: | C₃₈H₃₈N₆O₃S |
| SMILES: | O=C(C1=NC(N2CC3=C(C=CC=C3C(NC4=NC5=CC=CC=C5S4)=O)CC2)=CC=C1C6=C(C)N(CC7(C8)CC9CC8CC(C9)C7)N=C6)O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | A-1331852是具有口服活性的BCL-XL选择性抑制剂，Ki值小于10 pM。 |
| IC50和靶点: | [{name:"Bcl-xL:0.01 nM (Ki)"},{name: "Bcl-W:4 nM (Ki)"},{name: "Bcl-2:6 nM (Ki)"},{name: "Mcl-1:142 nM (Ki)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Leverson, J.D., Phillips, D.C., Mitten, M.J., et al.Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapySci. Transl. Med.7(279):279ra40,(2015)
